Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,582 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Completed No phase listed Observational

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Delfi Diagnostics Inc.
Industry
Eligibility
50 Years and older
Enrollment
2,992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Homewood, Alabama • Peoria, Arizona • Fayetteville, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 29, 2026, 5:18 PM EDT
Withdrawn Phase 1 Interventional

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05259397
View directory record Official record
Conditions
Bladder Cancer
Interventions
PF-07225570, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Not applicable Interventional

Absorbable Suture vs Permanent Suture in Sacrospinous Ligament Suspension

NCT05688059
View directory record Official record
Conditions
Pelvic Organ Prolapse, Uterovaginal Prolapse, Vaginal Vault Prolapse, Cystocele
Interventions
Absorbable Suture and Permanent Suture
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting No phase listed Observational

Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms

NCT07390591
View directory record Official record
Conditions
Spinal Cord Injuries, Neurogenic Lower Urinary Tract Dysfunction, Neurogenic Bladder
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00082823
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion

NCT06689176
View directory record Official record
Conditions
Bladder Cancer, Urinary Tract Infection
Interventions
Irrisept® Antimicrobial Wound Lavage
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 29, 2026, 5:18 PM EDT
Completed No phase listed Observational

Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study

NCT03473782
View directory record Official record
Conditions
Overactive Bladder
Interventions
Voiding Diary, Urodynamics Correlation Study
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

NCT02857816
View directory record Official record
Conditions
Overactive Bladder
Interventions
NURO System PTNM Therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
St. Petersburg, Florida • Evanston, Illinois • Cambridge, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

NCT03558087
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

NCT01295814
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Adalimumab, inactive drug
Drug · Other
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

NCT04074616
View directory record Official record
Conditions
Chronic Spinal Cord Injury, Neurogenic Bladder
Interventions
High Dose, Low dose
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 29, 2026, 5:18 PM EDT
Withdrawn Phase 2 Interventional

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

NCT01048177
View directory record Official record
Conditions
Vulvodynia
Interventions
Bladder instillation with heparin/ lidocaine
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 29, 2026, 5:18 PM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 29, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early or Late Foley Removal After Thoracotomy

NCT01611519
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 29, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT01916109
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Carboplatin, Panitumumab, radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 29, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

NCT02767921
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer, Stage II Bladder Urothelial Carcinoma, Stage II Renal Cell Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy, Recombinant EphB4-HSA Fusion Protein, Therapeutic Conventional Surgery
Other · Procedure · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 29, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Trans-MAPP Symptom Patterns Study (SPS)

NCT02514265
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Prostatitis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 2 Interventional

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

NCT00136175
View directory record Official record
Conditions
Bladder Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair

NCT00535301
View directory record Official record
Conditions
Cystocele, Uterine Prolapse, Urinary Incontinence
Interventions
grafted anterior prolapse repair, sutured anterior vaginal prolapse repair
Device · Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Downey, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

NCT01421719
View directory record Official record
Conditions
Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
Interventions
Cystoscopic injection of Botox into the urinary bladder
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 29, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer

NCT01840137
View directory record Official record
Conditions
Bladder Cancer
Interventions
Baseline Strength Test, Exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 29, 2026, 5:18 PM EDT